Statement of the United States to WTO TRIPS Council on the Paragraph 6 System
The following statement was delivered by USTR at the WTO Council for TRIPS Annual Review of the Paragraph 6 System on Wednesday, 27 October 2010.
Agenda item F, Annual Review of the Paragraph 6 System
Topic 5
Mr. Chairman
We are pleased to be here today to participate in the annual review on the implementation of paragraph 6 of the Doha Declaration.
The 2010 US elections
This was originally published in the Huffington Post here.
————
Continue Reading
Senator Sanders Letter to FDA: U.S. needs an ethical pathway for biological products
On November 2, 2010, U.S. Senator Bernard Sanders (VT-I) sent a letter to Margaret Hamburg, the FDA Commissioner, urging the agency to review the ethical implications of the 12 years of marketing exclusivity created by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).
Remarks by UNAIDS Secretariat and on behalf of UNDP: Capacity building on the Paragraph 6 System and related TRIPS flexibilities
The following statement was delivered on Wednesday, 27 October 2010 by the UNAIDS Secretariat and on behalf of UNDP during the Annual Review of Paragraph 6.
World Trade Organization
Council for TRIPS – Regular Session
Annual Review of Paragraph 6
Doha Declaration on the TRIPS Agreement and Public Health
Agenda item 4 – Capacity building on the Paragraph 6 System and related TRIPS flexibilities
Remarks by UNAIDS Secretariat and on behalf of UNDP
27 October 2010
Mr Chair, Distinguished Delegates
Paragraph 6 system: Brazilian intervention at the WTO TRIPS Council
On Wednesday, 27 October 2010, Brazil delivered the following intervention during the annual review of the Paragraph 6 system at the WTO TRIPS Council. The Brazilian intervention followed Canada’s detailed explanation of her use of the Paragraph 6 system in the Apotex/Rwanda case. The Brazilian intervention voiced concern over the future prospects of access to competitively priced second and third line ARVs raising questions as to whether the Paragraph 6 system would be economically viable for generic producers.